Skip to main content
SpringerLink
Log in

Relevance of the incubation period in cytotoxicity testing with primary human hepatocytes

  • In vitro systems
  • Published:
Archives of Toxicology Aims and scope Submit manuscript

Abstract

Primary human hepatocytes (PHHs) remain the gold standard for in vitro testing in the field of pharmacology and toxicology. One crucial parameter influencing the results of in vitro tests is the incubation period with test compounds. It has been suggested that longer incubation periods may be critical for the prediction of repeated dose toxicity. However, a study that systematically analyzes the relationship between incubation period and cytotoxicity in PHHs is not available. To close this gap, 30 compounds were tested in a concentration-dependent manner for cytotoxicity in cultivated cryopreserved PHHs (three donors per compound) for 1, 2 and 7 days. The median of the EC50 values of all compounds decreased 1.78-fold on day 2 compared to day 1, and 1.89-fold on day 7 compared to day 1. Median values of EC50 ratios of all compounds at day 2 and day 7 were close to one but for individual compounds the ratio increased up to almost six. Strong correlations were obtained for EC50 on day 1 and day 7 (R = 0.985; 95% CI 0.960–0.994), day 1 and day 2 (R = 0.964; 95% CI 0.910–0.986), as well as day 2 and day 7 (R = 0.981; 95% CI 0.955–0.992). However, compound specific differences also occurred. Whereas, for example, busulfan showed a relatively strong increase on day 7 compared to day 1, cytotoxicity of acetaminophen did not increase during longer incubation periods. To validate the observed correlations, a publicly available data set, containing data on the cytotoxicity of human hepatocytes cultivated as spheroids for incubation periods of 5 and 14 days, was analyzed. A high correlation coefficient of EC50 values at day 5 and day 14 was obtained (R = 0.894; 95% CI 0.798–0.945). In conclusion, the median cytotoxicity of the test compounds increased between 1 and 2 days of incubation, with no or only a minimal further increase until day 7. It remains to be studied whether the different results obtained for some individual compounds after longer exposure periods would correspond better to human-repeated dose toxicity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

Abbreviations

APAP:

Acetaminophen

ASP:

Aspirin

BOS:

Bosentan

BPR:

Buspirone

BUSF:

Busulfan

CBZ:

Carbamazepine

CHL:

Chlorpheniramine

CLON:

Clonidine

DFN:

Diclofenac

DMSO:

Dimethyl sulfoxide

DILI:

Drug-induced liver injury

EtOH:

Ethanol

FAM:

Famotidine

Glc:

Glucose

HYZ:

Hydroxyzine

INAH:

Isoniazid

KC:

Ketoconazole

LAB:

Labetalol

LEV:

Levofloxacin

MEL:

Melatonin

MePa:

Methylparaben

NAC:

N-Acetylcysteine

NIM:

Nimesulide

NFT:

Nitrofurantoin

PhB:

Phenylbutazone

PMZ:

Promethazine

PPL:

Propranolol

RIF:

Rifampicin

TSN:

Triclosan

VPA:

Valproic acid

Vit C:

Vitamin C

References

  • Arbo MD, Melega S, Stober R et al (2016) Hepatotoxicity of piperazine designer drugs: up-regulation of key enzymes of cholesterol and lipid biosynthesis. Arch Toxicol 90(12):3045–3060

    Article  CAS  Google Scholar 

  • Bernal W, Auzinger G, Dhawan A, Wendon J (2010) Acute liver failure. Lancet 376(9736):190–201

    Article  Google Scholar 

  • Chaudhari U, Nemade H, Gaspar JA, Hescheler J, Hengstler JG, Sachinidis A (2016) MicroRNAs as early toxicity signatures of doxorubicin in human-induced pluripotent stem cell-derived cardiomyocytes. Arch Toxicol 90(12):3087–3098

    Article  CAS  Google Scholar 

  • Colaianna M, Ilmjarv S, Peterson H et al (2017) Fingerprinting of neurotoxic compounds using a mouse embryonic stem cell dual luminescence reporter assay. Arch Toxicol 91(1):365–391

    Article  CAS  Google Scholar 

  • Daneshian M, Kamp H, Hengstler J, Leist M, van de Water B (2016) Highlight report: launch of a large integrated European in vitro toxicology project: EU-ToxRisk. Arch Toxicol 90(5):1021–1024

    Article  CAS  Google Scholar 

  • Deharde D, Schneider C, Hiller T et al (2016) Bile canaliculi formation and biliary transport in 3D sandwich-cultured hepatocytes in dependence of the extracellular matrix composition. Arch Toxicol 90(10):2497–2511

    Article  CAS  Google Scholar 

  • Frey O, Misun PM, Fluri DA, Hengstler JG, Hierlemann A (2014) Reconfigurable microfluidic hanging drop network for multi-tissue interaction and analysis. Nat Commun 5:4250

    Article  CAS  Google Scholar 

  • Gaspar JA, Doss MX, Hengstler JG, Cadenas C, Hescheler J, Sachinidis A (2014) Unique metabolic features of stem cells, cardiomyocytes, and their progenitors. Circ Res 114(8):1346–1360

    Article  CAS  Google Scholar 

  • Ghallab A (2015) Interspecies extrapolation by physiologically based pharmacokinetic modeling. EXCLI J 14:1261–1263

    PubMed  PubMed Central  Google Scholar 

  • Ghallab A, Celliere G, Henkel SG et al (2016) Model-guided identification of a therapeutic strategy to reduce hyperammonemia in liver diseases. J Hepatol 64(4):860–871

    Article  CAS  Google Scholar 

  • Godoy P, Hewitt NJ, Albrecht U et al (2013) Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Arch Toxicol 87(8):1315–1530

    Article  CAS  Google Scholar 

  • Godoy P, Schmidt-Heck W, Natarajan K et al (2015) Gene networks and transcription factor motifs defining the differentiation of stem cells into hepatocyte-like cells. J Hepatol 63(4):934–942

    Article  CAS  Google Scholar 

  • Godoy P, Widera A, Schmidt-Heck W et al (2016) Gene network activity in cultivated primary hepatocytes is highly similar to diseased mammalian liver tissue. Arch Toxicol 90(10):2513–2529

    Article  CAS  Google Scholar 

  • Gong X, Ivanov VN, Hei TK (2016) 2,3,5,6-Tetramethylpyrazine (TMP) down-regulated arsenic-induced heme oxygenase-1 and ARS2 expression by inhibiting Nrf2, NF-kappaB, AP-1 and MAPK pathways in human proximal tubular cells. Arch Toxicol 90(9):2187–2200

    Article  CAS  Google Scholar 

  • Grinberg M (2017) Statistical analysis of concentration-dependent, high-dimensional gene expression data. PhD thesis, University of Dortmund, 2017

  • Grinberg M, Stober RM, Edlund K et al (2014) Toxicogenomics directory of chemically exposed human hepatocytes. Arch Toxicol 88(12):2261–2287

    Article  CAS  Google Scholar 

  • Hammad S, Braeuning A, Meyer C, Mohamed F, Hengstler JG, Dooley S (2017) A frequent misinterpretation in current research on liver fibrosis: the vessel in the center of CCl4-induced pseudolobules is a portal vein. Arch Toxicol 91(11):3689–3692

    Article  CAS  Google Scholar 

  • Hengstler JG, Utesch D, Steinberg P et al (2000) Cryopreserved primary hepatocytes as a constantly available in vitro model for the evaluation of human and animal drug metabolism and enzyme induction. Drug Metab Rev 32(1):81–118

    Article  CAS  Google Scholar 

  • Hewitt NJ, Lechon MJ, Houston JB et al (2007) Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Metab Rev 39(1):159–234

    Article  CAS  Google Scholar 

  • Hoehme S, Brulport M, Bauer A et al (2010) Prediction and validation of cell alignment along microvessels as order principle to restore tissue architecture in liver regeneration. Proc Natl Acad Sci USA 107(23):10371–10376

    Article  CAS  Google Scholar 

  • Hoehme S, Friebel A, Hammad S, Drasdo D, Hengstler JG (2017) Creation of three-dimensional liver tissue models from experimental images for systems medicine. Methods Mol Biol 1506:319–362

    Article  CAS  Google Scholar 

  • Jansen PL, Ghallab A, Vartak N et al (2017) The ascending pathophysiology of cholestatic liver disease. Hepatology 65(2):722–738

    Article  CAS  Google Scholar 

  • Kampe T, Konig A, Schroeder H, Hengstler JG, Niemeyer CM (2014) Modular microfluidic system for emulation of human phase I/phase II metabolism. Anal Chem 86(6):3068–3074

    Article  CAS  Google Scholar 

  • Kim JY, Fluri DA, Marchan R et al (2015) 3D spherical microtissues and microfluidic technology for multi-tissue experiments and analysis. J Biotechnol 205:24–35

    Article  CAS  Google Scholar 

  • Krug AK, Kolde R, Gaspar JA et al (2013) Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol 87(1):123–143

    Article  CAS  Google Scholar 

  • LeCluyse EL (2001) Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulation. Eur J Pharm Sci 13(4):343–368

    Article  CAS  Google Scholar 

  • Leist M, Ghallab A, Graepel R et al (2017) Adverse outcome pathways: opportunities, limitations and open questions. Arch Toxicol 91(11):3477–3505

    Article  CAS  Google Scholar 

  • Liu G, Wang ZK, Wang ZY, Yang DB, Liu ZP, Wang L (2016) Mitochondrial permeability transition and its regulatory components are implicated in apoptosis of primary cultures of rat proximal tubular cells exposed to lead. Arch Toxicol 90(5):1193–1209

    Article  CAS  Google Scholar 

  • Luckert C, Schulz C, Lehmann N et al (2017) Comparative analysis of 3D culture methods on human HepG2 cells. Arch Toxicol 91(1):393–406

    Article  CAS  Google Scholar 

  • Ostapowicz G, Fontana RJ, Schiodt FV et al (2002) Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 137(12):947–954

    Article  Google Scholar 

  • Pfeiffer E, Kegel V, Zeilinger K et al (2015) Featured article: Isolation, characterization, and cultivation of human hepatocytes and non-parenchymal liver cells. Exp Biol Med (Maywood NJ) 240(5):645–656

    Article  CAS  Google Scholar 

  • Proctor WR, Foster AJ, Vogt J et al (2017) Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury. Arch Toxicol 91(8):2849–2863

    Article  CAS  Google Scholar 

  • Reif R, Karlsson J, Gunther G et al (2015) Bile canalicular dynamics in hepatocyte sandwich cultures. Arch Toxicol 89(10):1861–1870

    Article  CAS  Google Scholar 

  • Rempel E, Hoelting L, Waldmann T et al (2015) A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol 89(9):1599–1618

    Article  CAS  Google Scholar 

  • Schliess F, Hoehme S, Henkel SG et al (2014) Integrated metabolic spatial-temporal model for the prediction of ammonia detoxification during liver damage and regeneration. Hepatology 60(6):2040–2051

    Article  CAS  Google Scholar 

  • Shinde V, Hoelting L, Srinivasan SP et al (2017) Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol 91(2):839–864

    Article  CAS  Google Scholar 

  • Waldmann T, Rempel E, Balmer NV et al (2014) Design principles of concentration-dependent transcriptome deviations in drug-exposed differentiating stem cells. Chem Res Toxicol 27(3):408–420

    Article  CAS  Google Scholar 

  • Wilke RA, Lin DW, Roden DM et al (2007) Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat Rev Drug Discov 6(11):904–916

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The study was supported by the European Union’s Horizon 2020 research and innovation programme (EUToxRisk; no. 681002) with additional contributions of the projects StemCellNet (BMBF, 01EK1604A), Liver Simulator (BMBF, 031A355A), DILI (BMBF, 031L0074F), LiSyM (BMBF, 031Loo45), LivSysTransfer (BMBF, 0101-31Q0517), InnoSysTox (BMBF/EU, 031L0021A), SteatoTox (031L0114B) and DEEP (BMBF, 01KU1216).

Author information

Author notes

  1. Xiaolong Gu and Wiebke Albrecht shared first authorship.

Authors and Affiliations

  1. Leibniz Research Centre for Working Environment and Human Factors at the Technical University of Dortmund (IfADo), 44139, Dortmund, Germany

    Xiaolong Gu, Wiebke Albrecht, Karolina Edlund, Patricio Godoy, Cristina Cadenas, Rosemarie Marchan, Tim Brecklinghaus, Jan G. Hengstler & Regina Stoeber

  2. College of Veterinary Medicine, Yunnan Agricultural University, Kunming, 650201, Yunnan, People’s Republic of China

    Xiaolong Gu & Bo Han

  3. Department of Statistics, TU Dortmund University, 44227, Dortmund, Germany

    Franziska Kappenberg & Jörg Rahnenführer

  4. In Vitro Toxicology and Biomedicine, Department of Biology, University of Konstanz, Universitätsstr. 10, PO Box M657, 78457, Konstanz, Germany

    Marcel Leist

  5. InSphero AG, Technoparkstr. 1, 8005, Zürich, Switzerland

    Wolfgang Moritz

  6. Unit for Cell Therapy, University La Fe Hospital, Valencia, Spain

    Laia Tolosa Pardo & José V. Castell

  7. Simcyp, Sheffield, UK

    Iain Gardner

Authors
  1. Xiaolong Gu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wiebke Albrecht
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Karolina Edlund
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Franziska Kappenberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jörg Rahnenführer
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Marcel Leist
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Wolfgang Moritz
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Patricio Godoy
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Cristina Cadenas
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Rosemarie Marchan
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Tim Brecklinghaus
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Laia Tolosa Pardo
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. José V. Castell
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Iain Gardner
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Bo Han
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Jan G. Hengstler
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Regina Stoeber
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jan G. Hengstler.

Ethics declarations

Conflict of interest

There is no conflict of interest.

Electronic supplementary material

Below is the link to the electronic supplementary material.

204_2018_2302_MOESM1_ESM.pdf

Suppl. Fig. 1A: Cell-Titer-Blue cytotoxicity data for 30 compounds in primary human hepatocytes after incubation for one, two and seven days. The concentration-dependent curves represent data from three independent experiments corresponding to hepatocytes from three different donors with four technical replicates each. The cell viability for each concentration is presented as the percentage of untreated controls. Gray symbols indicate the viability of each technical replicate normalized to untreated controls; whereas, black symbols represent the mean values of all technical replicates for each concentration. The vertical line indicates the concentration which causes 20% (A–C) or 50% (D–F) loss of viability. The vertical dashed black lines show the 95% confidence interval of the EC50 or EC20s. The exact EC50 or EC20 (or EC80) values are given in the lower left corner of each panel. (A) EC20, one day incubation period; (B) EC20, two days incubation period; (C) EC20, seven days incubation period; (D) EC50, one day incubation period; (E) EC50, two days incubation period; and (F) EC50, seven days incubation period (PDF 130 KB)

Suppl. Fig. 1B (PDF 133 KB)

Suppl. Fig. 1C (PDF 126 KB)

Suppl. Fig. 1D (PDF 130 KB)

Suppl. Fig. 1E (PDF 132 KB)

Suppl. Fig. 1F (PDF 126 KB)

204_2018_2302_MOESM7_ESM.pptx

Suppl. Fig. 2: Bar plots of cytotoxicity EC50 and EC20 for 30 compounds in primary human hepatocytes after incubation for one, two and seven days. Note: For day one and day two or both, some of the less toxic compounds did not reduce viability compared to controls. In these cases, the highest tested concentrations were used and bars were labeled by an asterisk (PPTX 2685 KB)

Supplement 1: Detailed donor characteristics given by the supplier (PDF 331 KB)

Supplement 2: Standard operation procedure (SOP) for cultivation of primary human hepatocytes (DOCX 148 KB)

Supplement 3: Standard operation procedure (SOP) for cytotoxicity testing (DOCX 147 KB)

204_2018_2302_MOESM11_ESM.docx

Suppl. Table 1: (A) Stock solutions of the test compounds. For incubation periods of 24 and 48 h, the concentrations of stock solutions given in the light fields were used. For the 7 days incubation period, additional lower concentrations of stock solutions were used as indicated by the dark background. A final concentration of 0.1% DMSO in the culture medium was used with the exception of compounds with low solubility, where 0.5% DMSO was used, indicated by *. Culture medium-soluble compounds are indicated in blue, while compounds dissolved in DMSO are indicated in red. In the present study, concentrations have been selected to study cytotoxicity. To compare in vivo relevant concentrations, peak plasma concentrations of therapeutic doses (or documented human exposure for chemicals not used as drugs) are given. (B) Investigated concentrations of the test compounds. The applied stock solutions are given in Suppl. Table 1. For incubation periods of 24 and 48 h, the concentrations indicated in the white fields were tested. For the seven days incubation period, additional lower concentrations were tested as indicated in the fields with grey background. For water soluble test compounds, the required concentrations could be obtained in the culture medium (indicated by blue colour). For the further compounds (labeled red), stock solutions were prepared in dimethyl sulfoxide (DMSO). The final concentration of DMSO was 0.1%, with the exception of compounds with relatively low DMSO solubility which had a final concentration of 0.5% DMSO (indicated by * in Table 1 and Suppl. Table 1) (DOCX 22 KB)

204_2018_2302_MOESM12_ESM.xlsx

Suppl. Table 2: Cytotoxicity data (EC50 and EC20 values; mean and median values of three donors) from all test compounds, with ratios of EC50 as well as EC20 values of the different incubation periods (XLSX 15 KB)

Suppl. Table 3: EC50 and EC20 values for each individual donor (XLSX 16 KB)

Suppl. Table 4: Raw data from the CellTiter-Blue test of all individual compounds and donors (XLSX 115 KB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gu, X., Albrecht, W., Edlund, K. et al. Relevance of the incubation period in cytotoxicity testing with primary human hepatocytes. Arch Toxicol 92, 3505–3515 (2018). https://doi.org/10.1007/s00204-018-2302-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00204-018-2302-0

Keywords

Search

Navigation